Agile Therapeutics (NASDAQ:AGRX) Trading Down 9.1%

Agile Therapeutics Inc (NASDAQ:AGRX)’s share price dropped 9.1% during mid-day trading on Friday . The company traded as low as $0.95 and last traded at $1.00, approximately 2,929,661 shares were traded during trading. An increase of 685% from the average daily volume of 372,972 shares. The stock had previously closed at $1.10.

AGRX has been the topic of a number of recent analyst reports. Maxim Group set a $3.00 price target on shares of Agile Therapeutics and gave the stock a “buy” rating in a research note on Monday, June 10th. Janney Montgomery Scott initiated coverage on shares of Agile Therapeutics in a research note on Friday, April 12th. They set a “buy” rating and a $4.00 price target on the stock. Oppenheimer initiated coverage on shares of Agile Therapeutics in a research note on Thursday, June 6th. They set an “outperform” rating and a $5.00 price target on the stock. Finally, ValuEngine lowered shares of Agile Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $4.00.

The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.91 and a current ratio of 8.91. The business has a 50-day moving average price of $1.37.

Agile Therapeutics (NASDAQ:AGRX) last issued its earnings results on Thursday, August 1st. The specialty pharmaceutical company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.03. On average, research analysts forecast that Agile Therapeutics Inc will post -0.44 EPS for the current fiscal year.

In related news, CEO Alfred Altomari bought 20,000 shares of the stock in a transaction on Monday, June 10th. The shares were bought at an average cost of $1.27 per share, for a total transaction of $25,400.00. Following the completion of the transaction, the chief executive officer now owns 258,568 shares of the company’s stock, valued at approximately $328,381.36. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 8.50% of the company’s stock.

Institutional investors and hedge funds have recently modified their holdings of the business. BlackRock Inc. grew its position in Agile Therapeutics by 15.7% during the fourth quarter. BlackRock Inc. now owns 133,219 shares of the specialty pharmaceutical company’s stock worth $77,000 after buying an additional 18,038 shares during the period. Geode Capital Management LLC grew its position in Agile Therapeutics by 24.0% during the fourth quarter. Geode Capital Management LLC now owns 230,496 shares of the specialty pharmaceutical company’s stock worth $132,000 after buying an additional 44,639 shares during the period. Finally, Acadian Asset Management LLC grew its position in Agile Therapeutics by 33.3% during the first quarter. Acadian Asset Management LLC now owns 417,269 shares of the specialty pharmaceutical company’s stock worth $630,000 after buying an additional 104,222 shares during the period. Institutional investors own 42.38% of the company’s stock.

Agile Therapeutics Company Profile (NASDAQ:AGRX)

Agile Therapeutics, Inc, a women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription contraceptive patch, which completed Phase III clinical trials.

Further Reading: What are municipal bonds?

Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.